Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Related Keywords

United States ,America ,Davidp Luci , ,Prnewswire Acurx Pharmaceuticals Inc ,Trial Oversight Committee ,Drug Administration ,Society Or Healthcare Epidemiology Of America ,Us Centers For Disease ,Conference Health Expo ,Nasdaq ,University Of Houston College Pharmacy ,Department Of Clinical Sciences ,Acurx Pharmaceuticals Inc ,Acurx Pharmaceuticals ,C Diff Foundation ,Infectious Diseases Society Of America ,Annual International ,Ibezapolstat Update ,Can Emerging Microbiome Findings Contribute ,Professor Kevin ,Clinical Sciences ,Pharmacy Practice ,Houston College ,Clinical Trials ,Disease Control ,Environmental Safety ,Clinical Practice Guidelines ,Infectious Diseases Society ,Healthcare Epidemiology ,New England Journal ,Scientific Advisory Board ,Private Securities Litigation Reform Act ,United States Food ,Nc ,